Chen Joshua, Zheng Hao, Quan Hui, Li Gang, Gallo Paul, Ouyang Soo Peter, Binkowitz Bruce, Ting Naitee, Tanaka Yoko, Luo Xiaolong, Ibia Ekopimo
aMerck Research Laboratories, Rahway, NJ, USA.
Clin Trials. 2013;10(6):842-51. doi: 10.1177/1740774513500387. Epub 2013 Sep 6.
One key objective of a multi-regional clinical trial (MRCT) is to use the trial results to 'bridge' from the global level to local region in support of local registrations. However, data from each individual country are typically limited and the large number of countries will increase the chance of false positive findings.
Graphical tools to facilitate identification of potential outlying countries could be useful for country-level assessment. Existing methods such as funnel plot and expected range of treatment effect can substantially increase the false positive rate. The expected range approach can also have a very low power when there are a large number of small countries, which is typical in a MRCT.
In this article, we apply normal probability plots, commonly used as a diagnostic tool in linear regression analysis, to assess the differences among countries. Evidence of possible inconsistency, which incorporates both the estimated treatment effect and sample size, is plotted against its expected order statistic.
A simulation study is conducted to assess the impact of the negative correlation among residuals due to unequal sample sizes among countries and the performance of the proposed methods compared to existing approaches. The proposed methods tend to have a balanced consideration with substantially smaller false positive rate and reasonable probability to identify outlying countries in realistic scenarios.
While much lower than that of commonly used methods, the false positive rates of the proposed methods are not strictly controlled. This may be acceptable for these graphical tools with intention to flag potential outliers for investigation.
We recommend routine use of normal probability plots in MRCTs as a tool to identify potential outliers. If the normal probability plot is approximately linear but has heavy tails with a few outlying countries, these potential outliers should be examined carefully to understand the possible reasons.
多区域临床试验(MRCT)的一个关键目标是利用试验结果从全球层面“桥接”至当地区域,以支持当地注册。然而,每个国家的个体数据通常有限,且大量国家会增加出现假阳性结果的几率。
有助于识别潜在异常国家的图形工具可能对国家层面的评估有用。诸如漏斗图和治疗效果预期范围等现有方法会大幅增加假阳性率。当存在大量小国时,预期范围法的效能也可能非常低,而这在多区域临床试验中很常见。
在本文中,我们应用线性回归分析中常用作诊断工具的正态概率图来评估各国之间的差异。将包含估计治疗效果和样本量的可能不一致证据,与其预期顺序统计量进行绘制。
进行了一项模拟研究,以评估由于各国样本量不等导致的残差间负相关的影响,以及所提方法与现有方法相比的性能。所提方法往往能进行平衡考量,假阳性率大幅降低,且在现实场景中有合理概率识别出异常国家。
虽然所提方法的假阳性率远低于常用方法,但并未严格控制。对于这些旨在标记潜在异常值以供调查的图形工具而言,这或许是可接受的。
我们建议在多区域临床试验中常规使用正态概率图作为识别潜在异常值的工具。如果正态概率图大致呈线性,但有重尾且有几个异常国家,则应仔细检查这些潜在异常值,以了解可能的原因。